Strategy

News

Germany's Merck KGaA is looking at making further acquisitions to boost its business, with a focus on life sciences and rare diseases.

News

Bayer's chief executive Bill Anderson looks set to keep his role until nearly the decade, as his turnaround plan starts to deliver results.

News

Shortly after announcing a plan to separate its drug and cell therapy businesses into two separate companies, Galapagos has had a change of heart.

News

Things will get tougher before they get better at Bayer, according to CEO Bill Anderson, as the group reports its 2024 financial results.

News

Medigene slashes staff and delays trials of its lead TCR therapy candidate as it refocuses its pipeline

News

Novartis has raised its guidance for sales growth out to 2029 on the strength of its pipeline and the potential of late-stage R&D assets